The European Joint Action on Personalised Cancer Medicine (JA PCM) brings together 29 European countries and 151 partner organisations to advance personalised cancer care across Europe. The 4 year project (2025-2029) aims to create a sustainable cross-border network to foster innovation, good practice, equity, and collaboration in personalised cancer care. The project is co-funded by the European Commission and has an overall budget of €31.6 million.
The Joint Action will focus on three ‘arms’, representing the patient pathway:
- Personalised prevention and early detection
- Personalised medicine
- Personalised follow-up and tertiary prevention
Each arm consists of two technical work packages. In addition, the JA PCM has seven pilot projects that integrate and strengthen the technologies of personalised cancer medicine in European healthcare systems. Each arm is supported by at least one dedicated pilot application and there are two transversal pilots that cover all arms.
The pilots will cover seven themes:
Pathway, access and implementation of risk-informed cancer prevention across Europe
Implementation readiness for polygenic risk scores in screening
Supranational molecular tumour board for complex cases/countries without MTB
Continuous data collection via a federated sharing platform
Digital tools for remote monitoring, needs assessment, self-management, and supportive care
Personalised management of cancer predisposition across the patient journey (CPS Compass)
Implementation of ctDNA guided decision-making across the patient journey (LB-ctDNA)
The activities of the project will be supported by transversal activities, including external quality assessments for liquid biopsy, education and training initiatives, work on the ethical, legal and social implications of PCM; and a health technology and data assessment. You can read more on these activities under the ‘Work packages’ and ‘pilot’ pages on this website.
JA PCM will accelerate cross-border collaboration, strengthen European knowledge networks, and create synergies with EU initiatives to promote equitable access to personalised cancer medicine across Europe. Over the next four years, the initiative will lay the foundations for a sustainable, measurable and patient-centred European framework for personalised oncology.